10.15131/shef.data.11914158.v1 Shijie Ren Shijie Ren Katy Cooper Katy Cooper James Cooper James Cooper Helen Smith Helen Smith Soraya Shaikh Soraya Shaikh A systematic review and network meta - analysis of pharmacological therapies used for patients with advanced Parkinson's disease (2014) The University of Sheffield 2020 pharmacological therapy parkinson Health Economics 2020-03-01 16:17:54 Poster https://orda.shef.ac.uk/articles/poster/A_systematic_review_and_network_meta_-_analysis_of_pharmacological_therapies_used_for_patients_with_advanced_Parkinson_s_disease_2014_/11914158 <p>Parkinson’s disease affects about 110,000 people in the UK and 1.25 million people in Europe.1 Current options for management of advanced Parkinson’s disease include: </p> <p>• Increased dose or frequency of immediate-release levodopa (IR LD)</p> <p> • Supplemental controlled-release levodopa (CR LD)</p> <p> • Adjunctive therapies with levodopa, including dopamine agonists, monoamine oxidase-B inhibitors (MAO-BIs), and catechol-O-methyl transferase inhibitors (COMTIs) A new modified release form of levodopa (IPX066) is in development. </p>